NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS  1  2  3  4  5  » 
AstraZeneca »17/02/2007 [Company watch]
AstraZeneca Wins 2nd Award for Investment in China

Following $134millions investment in a manufacturing plant at Wuxi in 2001, AZ have announced a further $35millions investment in the site. In May 2006 AZ announced its intention to invest $100millions in R & D in China....   more»

»17/02/2007 [Industry news]
Italy Signs Agreement for Joint TCM Lab in China

The Chinese Ministry of Science and Technology's Vice Minister Shang Yong and visiting Italian Health Minister Livia Turco have signed an MOU on building a joint lab for integrating TCM with modern systematic biology and modern biotechnologies....   more»

Novartis »11/02/2007 [Company watch]
Novartis to focus on Hepatitus drugs in China

Novartis will launch a product for hepatitus B this year as it is China\\\'s prevalent disease with approx 20 million affected. CEO Vasella says they have been growing by 20% on average over the last 5 years and gained considerable market share....   more»

»04/03/2007 [Industry news]
China Blood Collection Centres contribute to spread of HIV

In parts of China,blood donors are not screened, increasing risk of diseases spreading. This is due to safety procedures being ignored by officials with financial interest in blood supply. In 2004 Gvmt shut down 150 illegal centres/agencies...   more»

Novo Nordisk »05/03/2007 [Company watch]
Novo Nordisk and Chinese Academy of Science establish Research Foundation

Novo Nordisk have committed $2million to co-fund research activities of mutual interest - diabetes and biopharmaceuticals....   more»

»05/03/2007 [Finance]
China's stock market has big impact

Some observors say that China's sudden stock market drop at the end of February helped create a global stock sell off. Observors suggest state interference either helped to create the panic or the undercover buying by them helped restore the markets....   more»

»04/03/2007 [Industry news]
Chinese Drug Safety under Spotlight

In 2006 China approved 6500 new drugs - the US approved approx. 100. Accidents and even deaths from disqualified drugs has created political interest in China who are calling for stiffer punishments and better safety procedures....   more»

Charles River »23/03/2007 [Company watch]
Charles River commits to large expansion programme in Shanghai

Charles River Laboratories International, Inc. (NYSE:CRL) announced today the expansion of its global footprint in Asia as part of its strategy to support customers' research and development efforts in this rapidly growing market....   more»

AstraZeneca »23/03/2007 [Company watch]
AStraZeneca name site for lab expansion plan

AStrazeneca confirm site for their $100Million R & D expansion in China as the Zhangjiang Hi-Tech park in Shanghai with completion due in mid 2007. Recruitrment of scientists is already underway. The Innovation Center China will open in mid-2007 before the establishment of a permanent site that officials are still looking for....   more»

TAKEDA Pharmaceutical Company »01/04/2007 [Company watch]
China Biopharma forms distribution agreement with Takeda

China biopharma announced today that its Chinese subsidiary, Hainan CITIC Biopharmaceutical Development Co., Ltd., has entered into a distribution agreement with Takeda Pharmaceutical Company, Ltd. ("Takeda"), the largest pharmaceutical company in Japan. As part of Takeda's goal to expand sales channels in Asia, China Biopharma has begun distributing Serrapeptase tablets, and the agreement with Takeda calls for China Biopharma to distribute additional drugs as they become available....   more»

Wyeth »01/04/2007 [Company watch]
Wyeth considering relocation from China to India

Exasperated by the slow pace of regulatory procedures in China for the approval of new drugs, American pharmaceutical and healthcare giant Wyeth is believed to be exploring the option of relocating its Asian drugs research operations from China to India. Sherry Ku, Wyeth’s senior director in China, has been quoted in the local media as saying on the sidelines of a pharmaceutical conference in Hainan province that, while there was, as of now, no timetable for shifting to India, such a move was possible, even inevitable, if the regulatory environment in mainland China did not improve....   more»

Bayer »28/03/2007 [Other]
Bayer CropScience aims to grow in China:

Bayer CropScience aims to grow in China: Sales in the People's Republic forecast to top EUR 100 million in the medium term Plans for two joint ventures for hybrid rice business and expansion of crop protection production...   more»

NCCSED »06/03/2007 [Industry news]
Frontier links with NCCSED (CRO) in China

US based Frontier Biosciences has signed agreement with National Chengdu Centre for Safety Evaluation of Drugs - a full service pre-clinical CRO regarded as one of the best in China - established by West China Hospital of the Sichuan University...   more»

»02/03/2007 [Company watch]
AXM Pharma acquires Chinese Research Institute

Shenyang based AXM Pharma, a manufacturer of proprietry and generic pharmaceutical products for China and other Asian markets will acquire Beijing Yuhuatang Biological Sci-Tech Development, a leading chinese research institute...   more»

»27/03/2007 [Industry news]
China Medical Technologies and Biomed-X Center will establish a new research laboratory

China Medical Technologies Inc. has entered into a 10-year collaboration agreement with the Biomed-X Center of Peking University to establish a new research laboratory that is expected to be used as a platform for the research and development of medical devices that complement China Medical's existing products....   more»

»03/04/2007 [Company watch]
3SBio Inc. Announces Fourth Quarter And Fiscal Year 2006 Results

Total net revenues increased 25.3% to RMB127.8 million (US$16.4 million). Research and development expenses: increased 90.9% to RMB6.1 million (US$0.8 million) for 2006 from RMB3.2 million for 2005....   more»

A Company to watch in China - potential customer for HLS

Beijing-based Lotus Pharmaceuticals is working on an ambitious strategy with a Wall Street financial advisor that can potentially catapult the company right into China's top pharma league with annual revenues exceeding $100 million....   more»

»29/03/2007 [Industry news]
SFDA approves three GLP centres

SFDA has approved three GLP centres. They are: 1. Hubei Center For Disease Control And Prevention—Institute Of Food And Drug Safety Evaluation (Hubei province ,China) 2. Chinese Academy Of Medical Sciences & Peking Union Medical College--Institute Of Laboratory Animal Science (Beijing, China): This GLP center has approved AAALAC. 3. Tianjin Institute Of Pharmaceutical Research—New Drug Safety Evaluation Center (Tianjin, China)...   more»

»10/04/2007 [Industry news]
Former SFDA Head accused of taking 5Million Yuan bribe

Zheng Xiaoyu, former director of the State Food and Drug Administration (SFDA), who was expelled from the Communist Party of China (CPC) last month, has been accused of taking bribes of more than 5 million yuan (about 650,000 U.S. dollars)....   more»

»11/04/2007 [Company watch]
Benda Pharmaceutical, Inc. acquired 57.57% of Shenzhen SiBiono GeneTech Co., Ltd. ("SiBiono"), maker of Gendicine® cancer commercialized gene therapy product.

Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTCBB: BPMA), a China-based pharmaceutical company engaged in the identification, discovery, development, and manufacturing of conventional medicines, active pharmaceutical ingredients and pharmaceutical intermediaries (or bulk chemicals), and Traditional Chinese Medicines, announced today that, through its 95% owned China-based subsidiary, Hubei Tongji Benda Ebei Pharmaceutical Co., Ltd. ("Benda Ebei"), it has treatment, the world's first approved and acquired 57.57% of Shenzhen SiBiono GeneTech Co., Ltd. ("SiBiono"), maker of Gendicine® cancer commercialized gene therapy product....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.